GMKBAmerican Journal of Public Health – This issue of AJHP is a theme issue on precision medicine, focusing on the use of pharmacogenetics in the clinical setting. The articles included provide substantial insight on how and why pharmacogenetics might and can be implemented in the clinical setting.
Implementation of inpatient models of pharmacogenetics programs
American Journal of Health-System Pharmacy – The operational elements essential for establishing an inpatient pharmacogenetic service are reviewed, and the role of the pharmacist in the provision of genotype-guided drug therapy in pharmacogenetics programs at three institutions is highlighted.
Pharmacogenomics competencies in pharmacy practice: A blueprint for change
Journal of the American Pharmacists Association – Given the rapidly evolving science, educational needs, and practice models in this area, a standardized competency-based approach to pharmacist education and training in pharmacogenomics is needed to equip pharmacists for leadership roles as essential members of healthcare teams that implement clinical utilization strategies for genomic data.
Genome-Wide Association of CKD Progression: The Chronic Renal Insufficiency Cohort Study
Journal of the American Society of Nephrology – We performed a genome–wide association study among participants in the Chronic Renal Insufficiency Cohort Study to better understand the contribution of genetics to CKD progression.
Effects of Using Personal Genotype Data on Student Learning and Attitudes in a Pharmacogenomics Course
American Journal of Pharmaceutical Education – Although clinical use of pharmacogenomic and genomic data to inform patient care decisions is increasing, it is not yet routine. Coverage of these concepts in health professions education, including pharmacy education, is lacking, and most practitioners feel inadequately prepared to apply these data in clinical practice.
The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology
The Journal of Molecular Diagnostics – Debates surrounding levels and types of evidence needed to properly evaluate the clinical value of molecular diagnostics are increasingly important because the growing body of knowledge, stemming from the increase of genomic medicine, provides many new opportunities for molecular testing to improve health care. We address the challenges in defining the clinical utility of molecular diagnostics for inherited diseases or cancer and provide assessment recommendations.
The Genetic Architecture of Diabetes in Pregnancy: Implications for Clinical Practice
American Journal of Perinatology – Here we provide an overview of the genetics of both pre-gestational and gestational diabetes, followed by a review of monogenic diabetes and associated pregnancy-specific implications.
Clopidogrel pharmacogenetics: from evidence to implementation
Future Cardiology – Clopidogrel is an ideal target for pharmacogenetic intervention for several reasons. First, there is a strong association between genotype, in this case CYP2C19 genotype, and clopidogrel effectiveness [1]. Second, the consequences of reduced clopidogrel effectiveness, namely adverse cardiovascular events, can be life threatening and costly. Because of these reasons, an increasing number of institutions have implemented CYP2C19 genotyping to predict clopidogrel response into clinical practice.
Implementing Algorithm-Guided Warfarin Dosing in an Ethnically Diverse Patient Population Using Electronic Health Records and Preemptive CYP2C9 and VKORC1 Genetic Testing
Clinical Pharmacology & Therapeutics – To facilitate multiethnic algorithm-guided warfarin dosing using preemptive genetic testing, we developed a strategy that accounts for the complexity of race and leverages electronic health records for algorithm variables and deploying point-of-care dose recommendations.
Family health history: An essential starting point for personalized risk assessment and disease prevention
Personalized Medicine – Family health history (FHH) information is well established as a basis for assessing a patient’s personal disease risk, but is underutilized for diagnosis and making medical recommendations. Epidemiological and genetic information have heightened the value of FHH to an individual’s health. This has motivated the development of new FHH collection tools and strategies for family members, but will require greater awareness and knowledge by both patients and practitioners.